CDC: Flu Vaccine 36 Percent Effective So Far

The vaccine shows better-than-expected effectiveness against the most common and most virulent strain of influenza in children under 9 years old.

| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

ISTOCK, SCYTHER5This year’s influenza vaccine has been 36 percent effective against the flu, according to a report released Thursday (February 15) by the US Centers for Disease Control and Prevention (CDC). When considering only protection against H3N2—the most common, and most virulent, strain of influenza—that effectiveness dropped to 25 percent.

The 2017-2018 flu season has been particularly brutal so far. Already 63 children have died—three-quarters of whom were not vaccinated, according to CDC officials (via CNN). And more than two-thirds of flu cases have been caused by the H3N2 strain, which is “often linked to more severe illness,” CDC Director Anne Schuchat tells CNN.

Scott Gottlieb, the commissioner of the US Food and Drug Administration (FDA), noted in a statement released on Thursday that, “it has been an especially challenging season, with high rates of hospitalization for both influenza and its complications. . . . Many schools have closed in an attempt to control the spread of the illness and doctors’ offices are packed with patients seeking diagnosis and antiviral treatment.”

This season’s vaccine was ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Keywords

Meet the Author

  • Catherine Offord

    Catherine is a science journalist based in Barcelona.
Share
3D illustration of a gold lipid nanoparticle with pink nucleic acid inside of it. Purple and teal spikes stick out from the lipid bilayer representing polyethylene glycol.
February 2025, Issue 1

A Nanoparticle Delivery System for Gene Therapy

A reimagined lipid vehicle for nucleic acids could overcome the limitations of current vectors.

View this Issue
Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

sartorius logo
Considerations for Cell-Based Assays in Immuno-Oncology Research

Considerations for Cell-Based Assays in Immuno-Oncology Research

Lonza
An illustration of animal and tree silhouettes.

From Water Bears to Grizzly Bears: Unusual Animal Models

Taconic Biosciences
Sex Differences in Neurological Research

Sex Differences in Neurological Research

bit.bio logo

Products

Photo of a researcher overseeing large scale production processes in a laboratory.

Scaling Lentiviral Vector Manufacturing for Optimal Productivity

Thermo Fisher Logo
Collage-style urban graphic of wastewater surveillance and treatment

Putting Pathogens to the Test with Wastewater Surveillance

An illustration of an mRNA molecule in front of a multicolored background.

Generating High-Quality mRNA for In Vivo Delivery with lipid nanoparticles

Thermo Fisher Logo
Tecan Logo

Tecan introduces Veya: bringing digital, scalable automation to labs worldwide